MedTech News
.................... by Andrew Celentano
Spinal Elements Expands Ventana® Platform with FDA 510(k) Clearance and First Cases of Ventana® A ALIF System
CARLSBAD, Calif., March 18, 2026 /PRNewswire/ — Spinal Elements®, a spine technology company known for developing innovative surgical solutions that prioritize clinical performance and surgical efficiency, today announced 510(k) clearance from the FDA and the first cases using its Ventana A Anterior Lumbar Interbody Fusion (ALIF) System. Ventana A strengthens Spinal Elements’ family of 3D printed titanium interbodies for lumbar and cervical fusion and is being introduced through a limited market launch.
MiniMed Announces FDA Clearance of MiniMed Flex™, the Company’s Smallest Insulin Pump Featuring Its First Smartphone-Controlled Design
MiniMed Flex™ is about half the size of the previous generation MiniMed™ 780G system, and features the SmartGuard™ adaptive algorithm to automatically adjust and autocorrect insulin delivery in real-time
Brain tumors hijack sugar metabolism to evade immune attack
Study finds immune cells in glioblastoma use fructose to evade immune response, pointing to a new treatment target
Prodeon gets FDA clearance for BPH-treating nitinol implant
Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross expander system.
Revolve Surgical wins FDA clearance for surgical robot
Revolve Surgical announced today that it received FDA 510(k) clearance for its surgical robot platform.
Perfuze wins FDA clearance for standalone aspiration catheter
Perfuze announced today that it received FDA 510(k) clearance for its Millipede88 aspiration catheter.
Smart bandage could heal and monitor wounds at the same time
Researchers have unlocked the possibility of creating smart wound dressings that enable real-time monitoring while also being able to deliver healing agents in one simple, scalable platform.
Engineered bacteria deliver cancer drug directly inside tumors in mice
Every year, millions of people are diagnosed with cancer globally; however, current treatments are limited by disease complexity. A study published in the open-access journal in PLOS Biology by Tianyu Jiang at Shandong University, Qingdao, China and colleagues suggests that Escherichia coli Nissle 1917 (EcN) may be engineered with anticancer agents to treat cancerous tumors in mice.